Recently，Jingxin Pharmaceutical said that the heavy alcoholic stake betting appacid Kabalatine capsule (specification 1.5mg and 3.0mg) drug registration approved by the State Food and Drug Administration has received the registration approval of drugs，Approval number is the national medicine accurate word H20183124 and the national medicine quasi -character H20183125，Registration is classified as original chemicals category 6，Approval number is valid until May 22, 2023，This means that anti -Alzheimer's Drug Kabalatine is about to be officially launched。

As the population aging intensifies，As a chronic neuraphytic disease that is mostly occurred in middle -aged and elderly groups，Elderly dementia is affecting the health of more and more people，In a high -income country，Elderly dementia is the fifth largest condition that causes death，But it is the most "expensive" disease，and this disease is still rising at an stake sports betting appunprecedented speed.。According to Alzheimer'S Disease International published the latest data display，1 patient with AD patients every 3 seconds was diagnosed，About 46.8 million global AD patients in 2015，It is expected that the number of global AD patients will reach 131.5 million by 2050，and the incidence of ADs over 65 years old in China is 4%～ 6%，At present, there are about 6 million patients with dementia，The number of patients will turn around every 20 years。As of now，European and American national recommendation AD treatment first -line medication only includes 4 types，Monacohi、Kabalatine and Galat Min，and glutamic acid NMDA receptor antagonist hydrochloride。

Before the heavy alcoholic stake betting appacid Kabalatine capsules of Jingxin Pharmaceutical were approved，Kabalatine is the exclusive variety in the domestic AD market，Data show，2016 domestic My stake betting appurban sample hospital Aceneng sales were 31.26 million yuan，increased by 22.25%year -on -year，The average growth rate of 2012-2016 is as high as 35.50%，It is estimated that the sales of 17 years are close to 200 million。Jingxin Pharmaceutical said，Heavy Liquoric acid Kabalatine Capsule has been approved to further enrich the company's psychiatric neurotrans，As the domestic first imitation as Cabalatine，It will have a positive impact on the company's business，This product is expected to grow into a million -level varieties。